Loading…
TARO-TEMOZOLOMIDE is a brand name for Temozolomide, supplied as a capsule. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: TARO-TEMOZOLOMIDE (temozolomide) is indicated for: • treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. • treatment of adult patients with glioblastoma multiforme or anaplastic astrocytoma and documented evidence of recurrence or…
Verbatim from this product's HC label. Tap a section to expand.
). 5 x 109/L and platelets ≥100 x 109/L. 0 x 109/L or the platelet count is <50 x 109/L during any cycle, the next cycle should be reduced one dose level. Dose levels include 100 mg/m2, 150 mg/m2, and 200 mg/m2. The lowest recommended dose is 100 mg/m2.
Dose modification for TARO-TEMOZOLOMIDE should be based on toxicities according to nadir ANC or platelet counts. Since women taking temozolomide were reported to have a higher incidence of grade 4 neutropenia and thrombocytopenia than men in the first cycle of therapy, they must be closely monitored for abnormal neutrophil and platelet counts.
2 Recommended Dose and Dosage Adjustment Adults Patients with Newly Diagnosed Glioblastoma Multiforme: Concomitant Phase TARO-TEMOZOLOMIDE is administered at a dose of 75 mg/m2 daily for 42 days concomitant with radiotherapy (60 Gy administered in 30 fractions) followed by maintenance TARO-TEMOZOLOMIDE for 6 cycles.
No dose reductions are recommended; however, dose interruptions may occur based on patient tolerance. 5 x 109/L; platelet count ≥100 x109/L; common toxicity criteria (CTC) non-hematological toxicity Grade ≤1 (except for alopecia, nausea and vomiting).
During treatment a complete blood count should be obtained weekly. TARO-TEMOZOLOMIDE dosing should be interrupted or discontinued during concomitant phase according to the hematological and non - hematological toxicity criteria as noted in Table 1.
Table 1. 5 x 10 9/L; platelet count ≥100 x 10 9/L; CTC non-hematological toxicity Grade ≤1 (except for alopecia , nausea, vomiting). CTC = Common Toxicity Criteria . TARO-TEMOZOLOMIDE (temozolomide) Page 6 of 57 Maintenance Phase Four weeks after completing the TARO-TEMOZOLOMIDE + RT (Radiotherapy) phase, TARO- TEMOZOLOMIDE is administered for an additional 6 cycles of maintenance treatment.
Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment. 5 x 109/L, and the platelet count is ≥100 x 109/L. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles.
The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. Dose reductions during the maintenance phase should be applied according to Tables 2 and 3. During treatment a complete blood count should be obtained on day 22 (21 days after the first dose of TARO-TEMOZOLOMIDE).
and 4 DOSAGE AND ADMINISTRATION/Administration). Patients treated with TARO-TEMOZOLOMIDE who experience myelosuppression, may experience prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome.
In some cases, exposure to concomitant medications associated with aplastic anemia, including carbamazepine, phenytoin, and sulfamethoxazole/trimethoprim, complicates assessment. Hepatic/Biliary/Pancreatic Hepatotoxicity, including liver enzyme elevation, hyperbilirubinemia, cholestasis and hepatitis, has been observed with temozolomide use in the post-market setting (see 8 ADVERSE REACTIONS/Post-Market Adverse Drug Reactions).
Hepatic injury, including fatal hepatic failure, has been reported in patients treated with temozolomide. Baseline liver function tests should be performed prior to treatment initiation. If abnormal, physicians should assess the benefit/risk prior to initiating temozolomide including the potential for fatal hepatic failure.
For patients on a 42 day treatment cycle liver function tests should be repeated midway during this cycle. For all patients, liver function tests should be TARO-TEMOZOLOMIDE (temozolomide) Page 10 of 56 checked after each treatment cycle.
For patients with significant liver function abnormalities, physicians should assess the benefit/risk of continuing treatment. Liver toxicity may occur several weeks or more after the last treatment with temozolomide. In the absence of formal studies in patients suffering from severe hepatic dysfunction the treating physician should use his discretion in weighing the benefits of using TARO-TEMOZOLOMIDE in this patient population against the potential risks.
Additionally, hepatitis due to hepatitis B virus (HBV) reactivation, in some cases resulting in death, has been reported. Patients should be screened for HBV infection before treatment initiation. Patients with evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following treatment with TARO- TEMOZOLOMIDE.
Reproductive Health:Female and Male Potential 09/2023 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES............................................................................................................
2 Sections or subsections that are not applicable at the time of authorization are not listed. ................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................................................
4 1 INDICATIONS .............................................................................................................................. 1 Pediatrics...............................................................................................................................
2 Geriatrics ............................................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................................
4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................................ 4 4 DOSAGE AND ADMINISTRATION .................................................................................................
1 Dosing Considerations........................................................................................................... 2 Recommended Dose and Dosage Adjustment .....................................................................
3 Reconstitution ...................................................................................................................... 4 Administration ......................................................................................................................
▪ TARO-TEMOZOLOMIDE is contraindicated in patients who have a history of hypersensitivity reaction to its components or to dacarbazine (DTIC). ▪ The use of TARO-TEMOZOLOMIDE is not recommended in patients with severe myelosuppression.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Temozolomide in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
The TARO-TEMOZOLOMIDE dose should be reduced or discontinued according to Table 2. Table 2. TARO-TEMOZOLOMIDE Dose Levels for Maintenance Treatment Dose Level Dose (mg/m2/day) Remarks -1 100 Reduction for prior toxicity 0 150 Dose during Cycle 1 1 200 Dose during Cycles 2–6 i n absence of toxicity Table 3.
0 x 109/L See footnote b Platelet Count <50 x 109/L See footnote b CTC Non-hematological Toxicity (except for alopecia, nausea , vomiting) CTC Grade 3 CTC Grade 4b a: TARO-TEMOZOLOMIDE dos e levels a re listed in Table 2. b: TARO-TEMOZOLOMIDE is to be dis continued if dos e reduction to <100 mg/m2 is required or if the s a me Grade 3 non-hematological toxicity (except for alopecia, nausea, vomiting) recurs after dos e reduction.
CTC = Common Toxicity Criteria .
Malignant Gliomas Showing Recurrence or Progression after Standard Therapy:
Adult patients: In patients previously untreated with chemotherapy, TARO-TEMOZOLOMIDE is administered at a dose of 200 mg/m2 once daily for 5 days per 28-day cycle. For patients previously treated with chemotherapy, the initial dose is 150 mg/m2 once daily for 5 days, to be increased in the second cycle to 200 mg/m2 once daily for 5 days, providing there is no hematologic toxicity (see 7 WARNINGS AND PRECAUTIONS).
In the reference controlled trial of GBM, the majority of patients treated with temozolomide (90%) received more than one cycle and 22% of patients received 6 or more cycles. These patients received a total of 484 cycles of temozolomide in total; 60% of cycles at 200 mg/m2/day and 36% at 150 mg/m2/day.
In the single arm AA trial, 93% of patients received more than one cycle and 25% of patients continued on study for 12 months or greater. Eighty-eight percent of patients were receiving either their initial dose or a higher dose at the last cycle.
However, limited experience is available on the prolonged use of temozolomide in this patient population. TARO-TEMOZOLOMIDE (temozolomide) Page 7 of 56 TARO-TEMOZOLOMIDE therapy can be continued until disease progression. 3 Reconstitution Not Applicable.
4 Administration TARO-TEMOZOLOMIDE Capsules TARO-TEMOZOLOMIDE […]
Therapy should be discontinued for patients with evidence of active hepatitis B infection. Infection Cases of herpes simplex encephalitis (HSE), including cases with fatal outcomes, were reported mostly in association with concomitant radiotherapy.
All patients, particularly those with previous herpes simplex infection need to be monitored for signs and symptoms of HSE during the treatment. Monitoring and Laboratory Tests Baseline liver function tests should be performed prior to treatment initiation.
If abnormal, physicians should assess the benefit/risk prior to initiating temozolomide including the potential for fatal hepatic failure. For patients on a 42 day treatment cycle liver function tests should be repeated midway during this cycle.
For all patients, liver function tests should be checked after each treatment cycle. Liver toxicity may occur several weeks or more after the last treatment with temozolomide. Patients should also be screened for HBV infection before treatment initiation.
Patients with evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following treatment with TARO-TEMOZOLOMIDE. Therapy should be discontinued for patients with evidence of active hepatitis B infection.
Concomitant phase for adult patients with newly diagnosed glioblastoma multiforme:
TARO- TEMOZOLOMIDE is administered at 75 mg/m2 daily for 42 days concomitant with radiotherapy (60 Gy administered in 30 fractions). A complete blood count should be obtained prior to initiation of treatment and weekly during treatment.
TARO-TEMOZOLOMIDE dosing should be interrupted or discontinued during concomitant phase according to the hematological and non-hematological toxicity criteria (see 4 DOSAGE AND ADMINISTRATION). Maintenance phase for adults with newly diagnosed glioblastoma multiforme or treatment fo r patients with malignant gliomas showing recurrence or progression after standard therapy: TARO-TEMOZOLOMIDE is administered at a dose of 150 or 200 mg/m2 once daily for 5 days per 28-day cycle.
5 x 109/L and platelets >100 x 109/L. 5 x 10 9/L and platelet count exceeds 100 x 109/L. 0 x 109/L or the platelet count is <50 x 109/L during any cycle, the next cycle should be reduced by one dose level, based upon the nadir blood count (see 4 DOSAGE AND ADMINISTRATION).
Dose levels include 100 mg/m2, 150 mg/m2 and 200 mg/m2. The lowest recommended dose is 100 mg/m2. TARO-TEMOZOLOMIDE (temozolomide) Page 11 of 56 Renal In the absence of formal studies in patients suffering from severe renal failure the treating physician should use his discretion in weighing the benefits of using TARO-TEMOZOLOMIDE in this patient population against the potential risks.
Reproductive Health:
Female and Male Potential Female patients: Women of childbearing potential should be advised to use effective contraception during treatment with TARO-TEMOZOLOMIDE therapy and in the six months after discontinuation of treatment.
Male patients:
TARO-TEMOZOLOMIDE can have genotoxic effects. Effective contraception should also be used by male patients taking TARO-TEMOZOLOMIDE. Men being treated with TARO-TEMOZOLOMIDE are advised not to father a child during or up to 6 months after treatment and to seek advice on cryoconservation of sperm prior to treatment because of the possibility of irreversible infertility due to therapy with TARO-TEMOZOLOMIDE.
Respiratory Patients who received concomitant temozolomide and radiotherapy in a pilot trial for the prolonged 42 day schedule were […]
5 Missed Dose ......................................................................................................................... 7 5 OVERDOSAGE .............................................................................................................................
7 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................................................. 7 7 WARNINGS AND PRECAUTIONS ..................................................................................................
1 Special Populations ............................................................................................................. 1 Pregnant Women ...............................................................................................................
2 Breast-feeding .................................................................................................................... 3 Pediatrics .............................................................................................................................
4 Geriatrics ............................................................................................................................. 12 8 ADVERSE REACTIONS.................................................................................................................................
1 Adverse Reaction Overview ............................................................................................... 2 Clinical Trial Adverse Reactions..........................................................................................
1 Clinical Trial Adverse Reactions – Pediatrics ...................................................................... 3 Less Common Clinical Trial Adverse Reactions ..................................................................
1 Less Common Clinical Trial Adverse Reactions – Pediatrics .............................................. 4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data……. ..........................................................................................................................................
5 Post-Market Adverse Reactions......................................................................................... 22 9 DRUG INTERACTIONS .......................................................................................................................
1 Serious Drug Interactions................................................................................................... 2 Drug Interactions Overview ...............................................................................................
3 Drug-Behavioural Interactions ............................................................................................ 4 Drug-Drug Interactions ......................................................................................................
5 Drug-Food Interactions ...................................................................................................... 6 Drug-Herb Interactions ......................................................................................................
7 Drug-Laboratory Test Interactions .................................................................................... 25 10 CLINICAL PHARMACOLOGY ...................................................................................................................
1 Mechanism of Action ........................................................................................................... 2 Pharmacodynamics .............................................................................................................
3 Pharmacokinetics ................................................................................................................ 27 11 STORAGE, STABILITY AND DISPOSAL […]